Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis BJOURNAL OF HEPATOLOGYIF332015-06-01182OAAI
Pharmacokinetic and Pharmacodynamic Properties of GS-9620, a Novel Toll-Like Receptor 7 Agonist, Demonstrate Interferon-Stimulated Gene Induction without Detectable Serum Interferon at Low Oral DosesJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82014-01-0161PREAI
THERAPEUTIC EFFICACY OF THE TLR7 AGONIST GS-9620 FOR HBV CHRONIC INFECTION IN CHIMPANZEESJOURNAL OF HEPATOLOGYIF332011-03-0111PREAI
A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTSJOURNAL OF HEPATOLOGYIF332011-03-012OAAI
ANTI-VIRAL EFFICACY AND INDUCTION OF AN ANTIBODY RESPONSE AGAINST SURFACE ANTIGEN WITH THE TLR7 AGONIST GS-9620 IN THE WOODCHUCK MODEL OF CHRONIC HBV INFECTIONJOURNAL OF HEPATOLOGYIF332011-03-0124OAAI
GS-9191 Is a Novel Topical Prodrug of the Nucleotide Analog 9-(2-Phosphonylmethoxyethyl)Guanine with Antiproliferative Activity and Possible Utility in the Treatment of Human Papillomavirus LesionsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52009-07-0140OAAI
Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's LymphomaCLINICAL CANCER RESEARCHIF10.22009-05-1859PREAI
GS-9219 - A novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphomaCLINICAL CANCER RESEARCHIF10.22008-05-0187PREAI
IGF-I binding proteins, IGF-I binding protein mRNA and IGF-I receptor mRNA in rats with acute renal failure given IGF-IKIDNEY INTERNATIONALIF12.61998-10-0112OA
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向